SRR6013552
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.520
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.440
- OXIDATIVE_PHOSPHORYLATION+0.440
- MTORC1_SIGNALING+0.320
- DNA_REPAIR+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- P53_PATHWAY+0.250
- ADIPOGENESIS+0.230
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- COMPLEMENT-0.380
- INFLAMMATORY_RESPONSE-0.320
- UV_RESPONSE_DN-0.310
- IL6_JAK_STAT3_SIGNALING-0.270
- KRAS_SIGNALING_UP-0.260
- INTERFERON_GAMMA_RESPONSE-0.250
- COAGULATION-0.230
- ANGIOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-94-A5I4-01A-11R-A26W-07 | — | cohortSQ2 | 0.885 |
| 2 | TCGA-33-AASJ-01A-11R-A405-07 | — | cohortSQ2 | 0.883 |
| 3 | TCGA-58-A46N-01A-11R-A24H-07 | — | cohortSQ2 | 0.881 |
| 4 | SRR6013575 | — | cohortSQ2 | 0.872 |
| 5 | C3N-02434 | — | cohortSQ2 | 0.872 |
| 6 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.869 |
| 7 | TCGA-56-8304-01A-11R-2326-07 | — | cohortSQ1 | 0.867 |
| 8 | TCGA-90-7769-01A-11R-2125-07 | — | cohortSQ2 | 0.867 |
| 9 | TCGA-37-A5EL-01A-11R-A26W-07 | — | cohortSQ1 | 0.867 |
| 10 | SRR6013549 | — | cohortSQ2 | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |